Compare GH & NWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GH | NWS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | 22300 |
| Industry | Medical Specialities | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 15.8B |
| IPO Year | 2018 | N/A |
| Metric | GH | NWS |
|---|---|---|
| Price | $86.76 | $30.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $119.79 | $38.18 |
| AVG Volume (30 Days) | ★ 2.0M | 862.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.66% |
| EPS Growth | ★ 6.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $982,021,000.00 | N/A |
| Revenue This Year | $33.30 | $6.06 |
| Revenue Next Year | $28.27 | $3.25 |
| P/E Ratio | ★ N/A | $12.98 |
| Revenue Growth | ★ 32.88 | N/A |
| 52 Week Low | $36.36 | $25.49 |
| 52 Week High | $120.74 | $35.58 |
| Indicator | GH | NWS |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 67.29 |
| Support Level | $82.33 | $29.98 |
| Resistance Level | $98.58 | $31.27 |
| Average True Range (ATR) | 4.64 | 0.62 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 44.51 | 85.90 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
News Corporation is a diversified media conglomerate with big presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings platform in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.